Treatment Details – 4.7 months
|Patients: This Phase II study involved 17 patients with malignant mesothelioma.|
Treatment: The treatment consisted of the chemotherapy drug, gemcitabine.
Toxicity: Two patients died without documentation of progressive disease and at least one of these deaths was considered related to drug toxicity and disease progression. In addition, grade 3-4 toxicities included hematologic, infection, dyspnea, edema, malaise/fatigue, cerebellar, cardiac dysrhythmia, and hyponatremia.
Results: There were no complete or partial responses and the median survival time was 4.7 months.
Correspondence: Hedy L. Kindler, MD